Related Experiment Videos
Mechanisms of cellular anthracycline resistance in childhood acute leukemia
M L Den Boer1, R Pieters, A J Veerman
1Department of Pediatric Hematology/Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
Abstract:
Cellular resistance to anthracyclines is often associated with an unfavorable clinical outcome in a variety of cancers, including leukemia. Several mechanisms of anthracycline resistance may be involved such as an impaired transport of drugs across the plasma membrane, an increased drug efflux, an increased intracellular detoxification of drugs, a reduced availability of intracellular drug targets, or a reduced ability of cells to induce apoptosis. Here, we review the studies published about mechanisms which may explain resistance to anthracyclines in leukemic cells of pediatric patients.
Insights
Cellular resistance to anthracyclines impacts leukemia treatment outcomes. This review examines mechanisms like drug transport, efflux, and apoptosis in pediatric leukemia cells.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Anthracyclines are crucial chemotherapy agents for various cancers, including leukemia.
- Cellular resistance to anthracyclines significantly complicates treatment and leads to poor clinical outcomes.
- Understanding resistance mechanisms is vital for improving pediatric leukemia therapy.
Purpose of the Study:
- To comprehensively review and synthesize current research on anthracycline resistance mechanisms in pediatric leukemia.
- To identify key cellular processes contributing to treatment failure in young leukemia patients.
Main Methods:
- Systematic literature review of studies investigating anthracycline resistance in pediatric leukemia.
- Analysis of published data on cellular mechanisms, including drug transport, efflux, detoxification, target availability, and apoptosis.
Main Results:
- Multiple mechanisms contribute to anthracycline resistance in pediatric leukemia cells.
- Impaired drug transport, increased drug efflux, enhanced intracellular detoxification, reduced target availability, and impaired apoptosis induction are key factors.
- These mechanisms collectively reduce the efficacy of anthracycline chemotherapy.
Conclusions:
- Anthracycline resistance in pediatric leukemia is multifactorial, involving complex cellular processes.
- Targeting these resistance mechanisms holds potential for developing novel therapeutic strategies.
- Further research is needed to translate these findings into improved clinical treatments for pediatric leukemia.